Highlights

  • Electra initiated a Phase 1 study of ELA822, a SIRPγ-specific antibody, in September 2026.
  • The company priced an upsized initial public offering of approximately USD 350 mn during September.
  • Its lead candidate ipsoprubart is advancing in a registrational programme for secondary hemophagocytic lymphohistiocytosis.
  • Electra is developing targeted precision medicines for immune-mediated diseases and cancer through its SIRP-focused approach.

Electra Therapeutics (NASDAQ:ETRA) is drawing fresh attention after its latest developments put electra ela822 phase 1 and ipo at the centre of its Investment narrative. The company’s disclosed milestones offer a clearer look at operating priorities, financial resources and what remains to be completed. Against that backdrop, shares gained 18.27% to USD 9.45 in the November 11, 2026 market figures. The distinction between progress already reported and milestones still planned remains essential when evaluating its next phase.

A Second Clinical Candidate Enters Testing

Electra Therapeutics announced initiation of a Phase 1 trial of ELA822 in September 2026. The investigational antibody targets SIRPγ and is designed for T-cell-mediated immune and inflammatory diseases.

The trial represents the second clinical-stage asset produced from the company’s library of SIRP-targeted antibodies. It broadens the clinical research effort beyond the lead programme.

Lead Development Remains with Ipsoprubart

Electra’s leading candidate, ipsoprubart, also known as ELA026, is a pan-SIRP monoclonal antibody undergoing a global registrational programme for secondary hemophagocytic lymphohistiocytosis, a severe hyperinflammatory condition.

Ipsoprubart is also being evaluated in a Phase 1 study of certain relapsed or refractory T-cell and natural-killer-cell malignancies. Both uses remain investigational and subject to clinical and regulatory assessment.

An Upsized IPO Adds Capital

On September 17, Electra priced an upsized initial public offering of 23,333,334 common shares at USD 15 each. The announced gross proceeds were approximately USD 350 mn before fees and expenses.

The IPO announcement said the stock was expected to begin Nasdaq trading on September 18 under the ETRA symbol. The pricing and expected timetable were disclosed separately from subsequent trading performance.

Research and Near-Term Engagement

Electra announced participation in the November 18 Jefferies Global Healthcare Conference in London. The company continues advancing its SIRP-based clinical strategy across immune-mediated conditions and oncology.

Future milestones depend on trial conduct, patient data and applicable regulatory requirements; clinical programmes do not yet represent approved treatments.

What Comes Next

For Electra Therapeutics, the near-term focus remains the milestones outlined in its latest announcements rather than an assumed outcome. The developments described above combine confirmed activity with expectations that remain subject to company execution, regulatory processes where applicable, and later reporting. Those distinctions will matter as subsequent updates provide more information about timing and progress.

Electra Therapeutics shares traded at USD 9.45, up 18.27%, in the November 11, 2026 market figures.